BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: van Dijken TD, Vastert SJ, Gerloni VM, Pontikaki I, Linnemann K, Girschick H, Armbrust W, Minden K, Prince FH, Kokke FT, Nieuwenhuis EE, Horneff G, Wulffraat NM. Development of Inflammatory Bowel Disease in Patients with Juvenile Idiopathic Arthritis Treated with Etanercept. J Rheumatol 2011;38:1441-6. [DOI: 10.3899/jrheum.100809] [Cited by in Crossref: 43] [Cited by in F6Publishing: 38] [Article Influence: 3.9] [Reference Citation Analysis]
Number Citing Articles
1 Levin AD, Wildenberg ME, van den Brink GR. Mechanism of Action of Anti-TNF Therapy in Inflammatory Bowel Disease. ECCOJC 2016;10:989-97. [DOI: 10.1093/ecco-jcc/jjw053] [Cited by in Crossref: 128] [Cited by in F6Publishing: 119] [Article Influence: 21.3] [Reference Citation Analysis]
2 Windschall D, Müller T, Becker I, Horneff G. Safety and efficacy of etanercept in children with the JIA categories extended oligoarthritis, enthesitis-related arthritis and psoriasis arthritis. Clin Rheumatol 2015;34:61-9. [DOI: 10.1007/s10067-014-2744-6] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 3.1] [Reference Citation Analysis]
3 Schreiner P, Biedermann L. Editorial: anti-TNF therapy-a double-edged sword? Aliment Pharmacol Ther 2019;50:822-3. [PMID: 31532545 DOI: 10.1111/apt.15401] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
4 Kondamudi PK, Malayandi R, Eaga C, Aggarwal D. Drugs as causative agents and therapeutic agents in inflammatory bowel disease. Acta Pharmaceutica Sinica B 2013;3:289-96. [DOI: 10.1016/j.apsb.2013.06.004] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
5 Swart JF, de Roock S, Wulffraat NM. What are the immunological consequences of long-term use of biological therapies for juvenile idiopathic arthritis? Arthritis Res Ther 2013;15:213. [PMID: 23731900 DOI: 10.1186/ar4213] [Cited by in Crossref: 24] [Cited by in F6Publishing: 17] [Article Influence: 3.0] [Reference Citation Analysis]
6 Lamot L, Miler M, Vukojević R, Vidović M, Lamot M, Trutin I, Gabaj NN, Harjaček M. The Increased Levels of Fecal Calprotectin in Children With Active Enthesitis Related Arthritis and MRI Signs of Sacroiliitis: The Results of a Single Center Cross-Sectional Exploratory Study in Juvenile Idiopathic Arthritis Patients. Front Med (Lausanne) 2021;8:650619. [PMID: 33763437 DOI: 10.3389/fmed.2021.650619] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Klotsche J, Niewerth M, Haas J, Huppertz H, Zink A, Horneff G, Minden K. Long-term safety of etanercept and adalimumab compared to methotrexate in patients with juvenile idiopathic arthritis (JIA). Ann Rheum Dis 2016;75:855-61. [DOI: 10.1136/annrheumdis-annrheumdis-2014-206747] [Cited by in Crossref: 58] [Cited by in F6Publishing: 46] [Article Influence: 8.3] [Reference Citation Analysis]
8 Mcrae BL, Levin AD, Wildenberg ME, Koelink PJ, Bousquet P, Mikaelian I, Sterman AS, Bryant S, D’haens G, Kamath R, Salfeld J, van den Brink GR. Fc Receptor-mediated Effector Function Contributes to the Therapeutic Response of Anti-TNF Monoclonal Antibodies in a Mouse Model of Inflammatory Bowel Disease. ECCOJC 2015;10:69-76. [DOI: 10.1093/ecco-jcc/jjv179] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 2.4] [Reference Citation Analysis]
9 Üsküdar Cansu D, Üsküdar Teke H, Temel T, Ertürk A, Kahraman O, Korkmaz C. Do Anti-TNF Agents Increase the Risk of Inflammatory Bowel Disease Evolution in Patients with Ankylosing Spondylitis? Real Life Data. J Natl Med Assoc 2019;111:262-9. [PMID: 30389147 DOI: 10.1016/j.jnma.2018.10.003] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
10 Funk RS, Becker ML. Disease modifying anti-rheumatic drugs in juvenile idiopathic arthritis: striving for individualized therapy. Expert Review of Precision Medicine and Drug Development 2016;1:53-68. [DOI: 10.1080/23808993.2016.1133234] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
11 Rodríguez S, Muñoz A, Bustos RH, Jaimes D. Pharmacovigilance of Biopharmaceuticals in Rheumatic Diseases, Adverse Events, Evolution, and Perspective: An Overview. Biomedicines 2020;8:E303. [PMID: 32842558 DOI: 10.3390/biomedicines8090303] [Reference Citation Analysis]
12 Kwon YH, Kim YJ. Pre-diagnostic Clinical Presentations and Medical History Prior to the Diagnosis of Inflammatory Bowel Disease in Children. Pediatr Gastroenterol Hepatol Nutr 2013;16:178-84. [PMID: 24224151 DOI: 10.5223/pghn.2013.16.3.178] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
13 Zeitz J, Enderlin S, Biedermann L, Turina M, Leibl S, Prakash M, Rogler G, Misselwitz B. New Onset, Aggravation and Recurrence of Crohn's Disease upon Treatment with Three Different Tumor Necrosis Factor Inhibitors. Case Rep Gastroenterol 2015;9:106-12. [PMID: 26034472 DOI: 10.1159/000381637] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
14 Verazza S, Davì S, Consolaro A, Bovis F, Insalaco A, Magni-Manzoni S, Nicolai R, Marafon DP, De Benedetti F, Gerloni V, Pontikaki I, Rovelli F, Cimaz R, Marino A, Zulian F, Martini G, Pastore S, Sandrin C, Corona F, Torcoletti M, Conti G, Fede C, Barone P, Cattalini M, Cortis E, Breda L, Olivieri AN, Civino A, Podda R, Rigante D, La Torre F, D'Angelo G, Jorini M, Gallizzi R, Maggio MC, Consolini R, De Fanti A, Muratore V, Alpigiani MG, Ruperto N, Martini A, Ravelli A; Italian Pediatric Rheumatology Study Group. Disease status, reasons for discontinuation and adverse events in 1038 Italian children with juvenile idiopathic arthritis treated with etanercept. Pediatr Rheumatol Online J 2016;14:68. [PMID: 27993144 DOI: 10.1186/s12969-016-0126-0] [Cited by in Crossref: 25] [Cited by in F6Publishing: 19] [Article Influence: 4.2] [Reference Citation Analysis]
15 Maller J, Fox E, Park KT, Paul SS, Baszis K, Borocco C, Prahalad S, Quartier P, Reinhardt A, Schonenberg-Meinema D, Shipman-Duensing L, Terreri MT, Simard J, Lavi I, Chalom E, Hsu J, Zisman D, Mellins ED; CARRA Legacy Registry Investigators. Inflammatory Bowel Disease in Children With Systemic Juvenile Idiopathic Arthritis. J Rheumatol 2021;48:567-74. [PMID: 32541073 DOI: 10.3899/jrheum.200230] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
16 Minden K, Niewerth M, Zink A, Seipelt E, Foeldvari I, Girschick H, Ganser G, Horneff G. Long-term outcome of patients with JIA treated with etanercept, results of the biologic register JuMBO. Rheumatology 2012;51:1407-15. [DOI: 10.1093/rheumatology/kes019] [Cited by in Crossref: 70] [Cited by in F6Publishing: 63] [Article Influence: 7.0] [Reference Citation Analysis]
17 Horneff G. Update on biologicals for treatment of juvenile idiopathic arthritis. Expert Opinion on Biological Therapy 2012;13:361-76. [DOI: 10.1517/14712598.2013.735657] [Cited by in Crossref: 40] [Cited by in F6Publishing: 31] [Article Influence: 4.4] [Reference Citation Analysis]
18 Bieber A, Fawaz A, Novofastovski I, Mader R. Antitumor Necrosis Factor-α Therapy Associated with Inflammatory Bowel Disease: Three Cases and a Systematic Literature Review. J Rheumatol 2017;44:1088-95. [DOI: 10.3899/jrheum.160952] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 1.6] [Reference Citation Analysis]
19 Horneff G. Safety of biologic therapies for the treatment of juvenile idiopathic arthritis. Expert Opin Drug Saf 2015;14:1111-26. [PMID: 26084637 DOI: 10.1517/14740338.2015.1042453] [Cited by in Crossref: 31] [Cited by in F6Publishing: 22] [Article Influence: 5.2] [Reference Citation Analysis]
20 Aalto K, Lahdenne P, Kolho KL. Fecal calprotectin in juvenile idiopathic arthritis patients related to drug use. Pediatr Rheumatol Online J 2017;15:9. [PMID: 28143478 DOI: 10.1186/s12969-016-0132-2] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
21 Arvikar SL, Fisher MC. Inflammatory bowel disease associated arthropathy. Curr Rev Musculoskelet Med. 2011;4:123-131. [PMID: 21710141 DOI: 10.1007/s12178-011-9085-8] [Cited by in Crossref: 64] [Cited by in F6Publishing: 50] [Article Influence: 5.8] [Reference Citation Analysis]
22 Adeniyi OF, Ima-Edomwonyi U, Odeghe AE, Onyekwelu IV. Development of crohn's disease following treatment for juvenile idiopathic arthritis in a nigerian child: Case report and review of literature. Ann Afr Med 2019;18:206-9. [PMID: 31823956 DOI: 10.4103/aam.aam_16_19] [Reference Citation Analysis]
23 Perez-Alvarez R, Pérez-de-Lis M, Ramos-Casals M; BIOGEAS study group. Biologics-induced autoimmune diseases. Curr Opin Rheumatol 2013;25:56-64. [PMID: 23114587 DOI: 10.1097/BOR.0b013e32835b1366] [Cited by in Crossref: 108] [Cited by in F6Publishing: 31] [Article Influence: 12.0] [Reference Citation Analysis]
24 Korzenik J, Larsen MD, Nielsen J, Kjeldsen J, Nørgård BM. Increased risk of developing Crohn's disease or ulcerative colitis in 17 018 patients while under treatment with anti-TNFα agents, particularly etanercept, for autoimmune diseases other than inflammatory bowel disease. Aliment Pharmacol Ther 2019;50:289-94. [PMID: 31267570 DOI: 10.1111/apt.15370] [Cited by in Crossref: 31] [Cited by in F6Publishing: 24] [Article Influence: 10.3] [Reference Citation Analysis]
25 Gibson DJ, Ryan EJ, Doherty GA. Keeping the bowel regular: the emerging role of Treg as a therapeutic target in inflammatory bowel disease. Inflamm Bowel Dis. 2013;19:2716-2724. [PMID: 23899545 DOI: 10.1097/mib.0b013e31829ed7df] [Cited by in Crossref: 25] [Cited by in F6Publishing: 13] [Article Influence: 3.1] [Reference Citation Analysis]
26 Krishnan A, Stobaugh DJ, Deepak P. Assessing the likelihood of new-onset inflammatory bowel disease following tumor necrosis factor-alpha inhibitor therapy for rheumatoid arthritis and juvenile rheumatoid arthritis. Rheumatol Int 2015;35:661-8. [DOI: 10.1007/s00296-014-3133-9] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
27 Lionetti G, Kimura Y, Schanberg LE, Beukelman T, Wallace CA, Ilowite NT, Winsor J, Fox K, Natter M, Sundy JS, Brodsky E, Curtis JR, Del Gaizo V, Iyasu S, Jahreis A, Meeker-O'Connell A, Mittleman BB, Murphy BM, Peterson ED, Raymond SC, Setoguchi S, Siegel JN, Sobel RE, Solomon D, Southwood TR, Vesely R, White PH, Wulffraat NM, Sandborg CI. Using registries to identify adverse events in rheumatic diseases. Pediatrics 2013;132:e1384-94. [PMID: 24144710 DOI: 10.1542/peds.2013-0755] [Cited by in Crossref: 20] [Cited by in F6Publishing: 14] [Article Influence: 2.2] [Reference Citation Analysis]
28 van Straalen JW, Krol RM, Giancane G, Panaviene V, Ailioaie LM, Doležalová P, Cattalini M, Susic G, Sztajnbok F, Maritsi D, Constantin T, Sawhney S, Rygg M, Oliveira SK, Nordal EB, Saad-Magalhaes C, Rubio-Perez N, Jelusic M, de Roock S, Wulffraat NM, Ruperto N, Swart JF; Paediatric Rheumatology International Trials Organisation (PRINTO). Increased incidence of inflammatory bowel disease on etanercept in juvenile idiopathic arthritis regardless of concomitant methotrexate use. Rheumatology (Oxford) 2021:keab678. [PMID: 34508559 DOI: 10.1093/rheumatology/keab678] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
29 Berrih-Aknin S. Myasthenia Gravis: paradox versus paradigm in autoimmunity. J Autoimmun. 2014;52:1-28. [PMID: 24934596 DOI: 10.1016/j.jaut.2014.05.001] [Cited by in Crossref: 72] [Cited by in F6Publishing: 66] [Article Influence: 9.0] [Reference Citation Analysis]
30 Wang Y, Han G, Chen Y, Wang K, Liu G, Wang R, Xiao H, Li X, Hou C, Shen B. Protective role of tumor necrosis factor (TNF) receptors in chronic intestinal inflammation: TNFR1 ablation boosts systemic inflammatory response. Lab Invest. 2013;93:1024-1035. [PMID: 23897411 DOI: 10.1038/labinvest.2013.89] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 2.8] [Reference Citation Analysis]
31 Huppertz HI, Lehmann HW. [Evidence of treatment of chronic inflammation in childhood and adolescence with biologics]. Z Rheumatol 2014;73:907-16. [PMID: 25479934 DOI: 10.1007/s00393-014-1398-8] [Cited by in Crossref: 2] [Article Influence: 0.3] [Reference Citation Analysis]
32 Barthel D, Ganser G, Kuester R, Onken N, Minden K, Girschick HJ, Hospach A, Horneff G. Inflammatory Bowel Disease in Juvenile Idiopathic Arthritis Patients Treated with Biologics. J Rheumatol 2015;42:2160-5. [DOI: 10.3899/jrheum.140472] [Cited by in Crossref: 32] [Cited by in F6Publishing: 27] [Article Influence: 4.6] [Reference Citation Analysis]
33 Bamias G, Corridoni D, Pizarro TT, Cominelli F. New insights into the dichotomous role of innate cytokines in gut homeostasis and inflammation. Cytokine. 2012;59:451-459. [PMID: 22795953 DOI: 10.1016/j.cyto.2012.06.014] [Cited by in Crossref: 69] [Cited by in F6Publishing: 71] [Article Influence: 6.9] [Reference Citation Analysis]
34 Hedin CRH, Sonkoly E, Eberhardson M, Ståhle M. Inflammatory bowel disease and psoriasis: modernizing the multidisciplinary approach. J Intern Med 2021;290:257-78. [PMID: 33942408 DOI: 10.1111/joim.13282] [Reference Citation Analysis]
35 Toussirot É, Aubin F. Paradoxical reactions under TNF-α blocking agents and other biological agents given for chronic immune-mediated diseases: an analytical and comprehensive overview. RMD Open 2016;2:e000239. [PMID: 27493788 DOI: 10.1136/rmdopen-2015-000239] [Cited by in Crossref: 81] [Cited by in F6Publishing: 63] [Article Influence: 13.5] [Reference Citation Analysis]
36 Dubeau MF, Iacucci M, Beck PL, Moran GW, Kaplan GG, Ghosh S, Panaccione R. Drug-induced inflammatory bowel disease and IBD-like conditions. Inflamm Bowel Dis 2013;19:445-56. [PMID: 22573536 DOI: 10.1002/ibd.22990] [Cited by in Crossref: 33] [Cited by in F6Publishing: 32] [Article Influence: 3.7] [Reference Citation Analysis]
37 Bamias G, Cominelli F. Exploring the Early Phase of Crohn's Disease. Clin Gastroenterol Hepatol 2020:S1542-3565(20)31283-0. [PMID: 32949730 DOI: 10.1016/j.cgh.2020.09.023] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
38 Fiorino G, Danese S, Pariente B, Allez M. Paradoxical immune-mediated inflammation in inflammatory bowel disease patients receiving anti-TNF-α agents. Autoimmunity Reviews 2014;13:15-9. [DOI: 10.1016/j.autrev.2013.06.005] [Cited by in Crossref: 94] [Cited by in F6Publishing: 83] [Article Influence: 11.8] [Reference Citation Analysis]
39 Hügle B, Speth F, Haas JP. Inflammatory bowel disease following anti-interleukin-1-treatment in systemic juvenile idiopathic arthritis. Pediatr Rheumatol Online J 2017;15:16. [PMID: 28288653 DOI: 10.1186/s12969-017-0147-3] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 3.2] [Reference Citation Analysis]
40 Tavakolpour S, Darvishi M, Ghasemiadl M. Pharmacogenetics: A strategy for personalized medicine for autoimmune diseases. Clin Genet 2018;93:481-97. [PMID: 29194620 DOI: 10.1111/cge.13186] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 5.3] [Reference Citation Analysis]
41 Pérez-de-lis M, Retamozo S, Flores-chávez A, Kostov B, Perez-alvarez R, Brito-zerón P, Ramos-casals M. Autoimmune diseases induced by biological agents. A review of 12,731 cases (BIOGEAS Registry). Expert Opinion on Drug Safety 2017;16:1255-71. [DOI: 10.1080/14740338.2017.1372421] [Cited by in Crossref: 64] [Cited by in F6Publishing: 48] [Article Influence: 12.8] [Reference Citation Analysis]
42 Minden K, Klotsche J, Niewerth M, Horneff G, Zink A. [Biologics register JuMBO. Long-term safety of biologic therapy of juvenile idiopathic arthritis]. Z Rheumatol 2013;72:339-46. [PMID: 23456365 DOI: 10.1007/s00393-012-1063-z] [Cited by in Crossref: 3] [Article Influence: 0.3] [Reference Citation Analysis]